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oping a bridging therapy suitable for treating large numbers of
people exposed to high doses of ionizing irradiation. These pre-
clinical experiments indicate that allogeneic MP generated from
puriﬁed HSC by ex vivo expansion can function as a bridging
therapy during hematopoietic recovery following high-dose radi-
ation.
169
[Abstract Withdrawn]
170
KERATINOCYTE GROWTH FACTOR (KGF) IS REQUIRED FOR POST-
NATAL THYMIC REGENERATION
Alpdogan, O.1; Hubbard, V.M.1; Muriglan, S.J.1; Goldberg, G.L.2;
Kochman, A.A.1; Eng, J.M.1; Smith, O.M.1; Boyd, R.L.2; van den
Brink, M.R.M.1 1. Memorial Sloan-Kettering Cancer Center, New
York, NY; 2. Monash University, Melbourne, Victoria, Australia.
KGF is a ﬁbroblast growth factor family member (FGF-7) that
mediates epithelial cell proliferation and differentiation in a variety
of tissues. Recent pre-clinical studies have demonstrated that KGF
administration (before conditioning) to the recipients of allogeneic
bone marrow transplantation (BMT) can enhance T cell and thy-
mic reconstitution. Therefore, we studied the role of KGF on T
cell development by using KGF (/) mice in experimental mu-
rine models. Phenotypic analysis of KGF (/) mice at varying
ages (6–44 weeks) demonstrated that the bone marrow, thymus
and lymph node cellularity and the cell distribution, as well as
thymic stromal cell composition among KGF (/), wild type
(WT) and KGF (/) mice were similar. However, splenic cellu-
larity and splenic T cell numbers were slightly lower than WT and
KGF (/) controls. More importantly, KGF (/) mice had a
greater than six fold decrease in thymic cellularity after sublethal
irradiation (450 cGy), while erythroid, myeloid and platelet recov-
ery were intact. In our preliminary experiments the analysis of
thymic stroma revealed that ﬁbroblast numbers were decreased in
KGF (/) compared to controls following sublethal irradiation.
We used bone marrow transplantation models to assess the relative
contribution of KGF produced by thymocytes or thymic stromal
cells during thymic regeneration after irradiation. T cell reconsti-
tution was impaired in syngeneic or allogeneic KGF (/) BMT
recipients in comparison to KGF (/) controls but there was no
difference in the distribution of thymocyte subsets or splenic T cell
content. The recipients of KGF (/) bone marrow had decreased
thymic and splenic cellularity after allogeneic BMT. These data
demonstrate that both donor and host derived KGF play a role in
thymic regeneration. Finally, rhKGF (palifermin) administration
to young and old mice (10 month old) enhanced thymopoiesis
when analyzed 28 days after rhKGF (palifermin) administration.
Pre-BMT rhKGF (palifermin) administration to the recipients of
syngeneic and allogeneic BMT also resulted in a 2–6 fold increase
in thymic cellularity compared to the control group. We conclude
that KGF produced by both thymocytes and thymic stromal cells
is not required for pre- and post-natal thymic development, but
plays a role in post-natal thymic stroma regeneration after irradi-
ation. These data support the potential use of KGF to protect or
restore thymic damage after chemo/radiotherapy.
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IN VIVO DUAL MODALITY CONTEMPORANEOUS IMAGING OF DIFFER-
ENT TUMOR REACTIVE T-CELL SUBPOPULATIONS
Doubrovin, M.M.; Doubrovina, E.S.; Cai, S.; Blasberg, R.G.; O’Reilly,
R.J. Memorial Sloan-Kettering Cancer Center, New York, NY.
Background: Identiﬁcation of the in vivo functions of T-cell
subpopulations in vivo is critical for understanding their interac-
tions in the course of adoptive immune cell therapy. The quanti-
tation of T-cell subpopulations in tissues would also allow for the
assessment of the proliferation potential of these cells. Previously,
we have used various applications of HSV1-tk PET and ﬁreﬂy
Luciferase reporter gene imaging for the generation of cell traf-
ﬁcking images. We have combined these two imaging options to
assess CD4 and CD8 T-cell populations and to correlate cell
numbers and image intensity using microPET and bioluminescent
imaging (BLI). Methods: Cytotoxic T-lymphocytes stably trans-
duced with reporter genes (CTL-TGN or CTL-FLucN) were
administered to NOD-SCID mice bearing previously established
subcutaneous EBV-BLCL xenografts in a dose range from 104 to
107 cells, locally. In vivo imaging of these T-cells either prelabeled
in vitro with [18F]FEAU and D-Luciferine or in vivo by intravenous
infusion of the same probes with microPET and BLI was per-
formed 4 hours after CTL injection. T-cells in post mortem tissue
samples were quantitated by FACS. The radioactivity was also
measured in these samples using gamma-counter. Total activity
obtained from 3-dimensional ROIs for microPET and total pho-
ton ﬂux measured in 2D-ROIs for BLI were used to draw dose-
calibration curves. Results: The values of T-cell retention in
tumor following a direct injection obtained for ex vivo labeled cells
were applied for correction of in vivo labeling results. For both ex
vivo and in vivo labeled T-cells, close correlations between CD8
CTL-TGN number and accumulated radioactivity (nCi/cc for
MicroPET) and between CD4 CTL-FLucN number and BLI
signal intensity expressed as a total photon ﬂux (photon/sec for
BLI) were observed. The limits of sensitivity for both BLI and
MicroPET imaging appeared to be comparable at a depth in tissue
of 7–10 mm (depth of CTL administration), approximating 105
cells. The correlations calculated between the number of CTLs
(dose) and signal intensity were used to build a scale for the
assessment of the cell number and concentration in tissues. Con-
clusions:Dual modality imaging can be used for contemporaneous
quantitative imaging of different T-cell subpopulations after adop-
tive cell therapy using noninvasive in vivo reporter gene-based
imaging techniques, such as MicroPET and BLI.
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ELIMINATION OF ALLOREACTIVE T LYMPHOCYTES USING PHOTODY-
NAMIC THERAPY PREVENTS THE DEVELOPMENT OF GVHD AND PRO-
MOTES B AND T CELL RECONSTITUTION AFTER MHC-MISMATCHED
TRANSPLANTATION
Sidi Boumedine, R.1; Krosl, G.1; Vaillancourt, M.2; Perreault, C.1; Roy,
D.C.1 1. Hopital Maisonneuve-Rosemont, Montreal, QC, Canada; 2.
Celmed BioSciences, Montreal, QC, Canada.
Previous studies have demonstrated that photodynamic therapy
can be used to eliminate alloreactive T cells and preserve graft-
versus-leukemia activity in the context of major histocompatibility
complex (MHC) mismatched stem cell transplantation (SCT).
However, the speciﬁcity of the T cell activation process and the
capacity of PDT to promote rapid immune reconstitution has not
been evaluated extensively. The purpose of this study was to de-
termine the capacity of PDT to speciﬁcally target antigen-primed
T lymphocytes and to promote B and T cell post-transplant re-
covery. C57BL/6 donor (B6; H-2b) spleen cells were ﬁrst activated
against C3H/HeJ (C3H; H-2k) host spleen cells in a one-way
mixed lymphocyte culture and then exposed to photodynamic
treatment (PDT) using dibromorhodamine methyl ester
(TH9402) as photosensitizer. Activated (CD25) T cells retained
greater concentrations of the photosensitizer and were preferen-
tially eliminated over resting lymphocytes. When lethally irradi-
ated C3H mice were transplanted with B6 bone marrow cells
supplemented with B6 spleen cells activated against C3H targets,
they rapidly succumbed to acute GVHD (within 10–47 days). In
contrast, when donor (B6) T cells were activated against C3H cells
and then exposed to PDT, 80% of C3H recipients survived (100
days) (p
0.0001). Interestingly, PDT also abrogated (100% sur-
vival) the lethal effect of the same grafts on B10BR (H-2k) recip-
ients (p
0.0001), conﬁrming the importance of the activation step
and the speciﬁcity of the PDT process for anti-H-2k primed cells.
Additionally, transplantation of PDT treated B6 T cells induced
lethal GVHD in histo-incompatible Balb/c mice (H-2d), suggest-
ing that PDT spared resting T lymphocytes for anti-non-host
reactivity. Analysis of immune recovery at day 100, evaluating T
and B cell populations in thymus and spleen, activated T cells
components (CD44, CD62L, CD69), proliferative responses (anti-
CD3 and conA), and V-repertoire indicated that T and B cell
reconstitution in MHC-mismatched mice transplanted with
primed cells exposed to PDT was similar to that of mice trans-
planted with treated or control autologous cells, demonstrating
that immune cells were preserved and functional. These results
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